Covered recipient · General Payments record
GEORGE M LEWITT
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$286,022.99
316 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $231,534.25 | 83 |
| Travel and Lodging | $30,351.65 | 79 |
| Consulting Fee | $18,900.50 | 8 |
| Food and Beverage | $5,229.63 | 145 |
| Education | $6.96 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $114,491.49 | 93 |
| Lilly USA, LLC | $75,866.17 | 101 |
| Janssen Scientific Affairs, LLC | $31,703.06 | 25 |
| E.R. Squibb & Sons, L.L.C. | $21,435.29 | 18 |
| Dermavant Sciences, Inc. | $20,055.02 | 13 |
| UCB, Inc. | $9,158.79 | 8 |
| Novartis Pharmaceuticals Corporation | $3,997.12 | 8 |
| PFIZER INC. | $3,683.53 | 6 |
| Galderma Laboratories, L.P. | $2,513.47 | 7 |
| Incyte Corporation | $2,235.34 | 3 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $187.26 | 6 |
| Janssen Biotech, Inc. | $153.57 | 9 |
| Amgen Inc. | $124.35 | 6 |
| Regeneron Healthcare Solutions, Inc. | $106.68 | 3 |
| GENZYME CORPORATION | $106.06 | 3 |
| Celgene Corporation | $95.01 | 1 |
| Sun Pharmaceutical Industries Inc. | $33.20 | 1 |
| Journey Medical Corporation | $30.22 | 2 |
| Biofrontera Inc. | $18.29 | 1 |
| STRATA Skin Sciences, Inc. | $14.71 | 1 |
| Allergan, Inc. | $14.36 | 1 |
Page 2 of 7; records 51–100 of 316 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GEORGE M LEWITT
NPI 1902031313 · CMS profile ID 221538
Allopathic & Osteopathic Physicians / Dermatology
NORTHBROOK, IL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 7; records 51–100 of 316 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1902031313?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GEORGE M LEWITT, NPI 1902031313, CMS profile ID 221538. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 316 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902031313?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). GEORGE M LEWITT, NPI 1902031313, CMS profile ID 221538. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 316 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902031313?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- GEORGE M LEWITT, NPI 1902031313, CMS profile ID 221538, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 7; records 51–100 of 316 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1902031313?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
316 matching records · $286,022.99 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 316.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Celgene Corporation | $95.01 | 11/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932847333 | CMS |
| ABBVIE INC. | $23.99 | 11/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195459 | CMS |
| ABBVIE INC. | $4,000.00 | 11/15/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195461 | CMS |
| ABBVIE INC. | $186.10 | 11/13/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195457 | CMS |
| ABBVIE INC. | $34.67 | 11/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195451 | CMS |
| ABBVIE INC. | $870.00 | 11/11/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195453 | CMS |
| ABBVIE INC. | $14.50 | 11/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195455 | CMS |
| ABBVIE INC. | $209.66 | 11/10/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195449 | CMS |
| ABBVIE INC. | $26.42 | 11/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195445 | CMS |
| ABBVIE INC. | $467.46 | 11/09/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195447 | CMS |
| E.R. Squibb & Sons, L.L.C. | $4,250.00 | 11/09/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932847337 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $14.56 | 11/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947503931 | CMS |
| E.R. Squibb & Sons, L.L.C. | $10.32 | 11/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932847329 | CMS |
| Janssen Scientific Affairs, LLC | $3,038.00 | 11/05/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887211285 | CMS |
| Janssen Scientific Affairs, LLC | $132.08 | 11/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887211291 | CMS |
| Janssen Scientific Affairs, LLC | $694.30 | 11/04/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887211297 | CMS |
| ABBVIE INC. | $9.26 | 11/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195443 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,650.50 | 11/02/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932847321 | CMS |
| Amgen Inc. | $34.05 | 10/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939898231 | CMS |
| Janssen Biotech, Inc. | $6.23 | 10/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885874619 | CMS |
| ABBVIE INC. | $5,600.00 | 10/27/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195441 | CMS |
| E.R. Squibb & Sons, L.L.C. | $101.28 | 10/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932847339 | CMS |
| Journey Medical Corporation | $15.18 | 10/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 924782031 | CMS |
| GENZYME CORPORATION | $36.14 | 10/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939008995 | CMS |
| ABBVIE INC. | $32.00 | 10/21/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195433 | CMS |
| ABBVIE INC. | $62.14 | 10/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195435 | CMS |
| ABBVIE INC. | $656.00 | 10/21/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195437 | CMS |
| ABBVIE INC. | $348.20 | 10/21/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195439 | CMS |
| Incyte Corporation | $2,200.00 | 10/21/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942932261 | CMS |
| Sun Pharmaceutical Industries Inc. | $33.20 | 10/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947776183 | CMS |
| PFIZER INC. | $31.82 | 10/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949601155 | CMS |
| ABBVIE INC. | $6,000.00 | 10/19/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195431 | CMS |
| E.R. Squibb & Sons, L.L.C. | $600.00 | 10/19/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932847377 | CMS |
| ABBVIE INC. | $4,000.00 | 10/18/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195429 | CMS |
| UCB, Inc. | $22.01 | 10/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965199139 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.16 | 10/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932847325 | CMS |
| ABBVIE INC. | $461.46 | 10/12/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195427 | CMS |
| Amgen Inc. | $13.79 | 10/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939898229 | CMS |
| ABBVIE INC. | $19.93 | 10/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195423 | CMS |
| ABBVIE INC. | $6.96 | 10/06/2022 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195425 | CMS |
| Lilly USA, LLC | $24.67 | 10/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918021173 | CMS |
| ABBVIE INC. | $38.54 | 10/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195411 | CMS |
| ABBVIE INC. | $80.69 | 10/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195413 | CMS |
| ABBVIE INC. | $37.34 | 10/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195415 | CMS |
| ABBVIE INC. | $2.96 | 10/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195417 | CMS |
| ABBVIE INC. | $73.47 | 10/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195419 | CMS |
| ABBVIE INC. | $26.35 | 10/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195421 | CMS |
| ABBVIE INC. | $5,600.00 | 09/30/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195405 | CMS |
| ABBVIE INC. | $265.36 | 09/30/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195407 | CMS |
| ABBVIE INC. | $265.00 | 09/30/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893195409 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $495,509.49 | 55 |
| PY2024 | Recipient | $104.58 | 1 |
| PY2024 | Principal investigator | $434,117.42 | 79 |
| PY2023 | Recipient | $7,463.00 | 1 |
| PY2023 | Principal investigator | $79,353.85 | 34 |
| PY2022 | Principal investigator | $4,148.00 | 1 |
| PY2021 | Principal investigator | $905.48 | 1 |
| PY2019 | Principal investigator | $4,835.80 | 3 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
55 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $3,537.36 | 12/31/2025 | Non-covered Recipient Entity ARANO LLC | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy | No dispute reported | 06/30/2026 | 1202533751 |
| Principal investigator 1 | ABBVIE INC. | $7,950.00 | 12/04/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202526994 |
| Principal investigator 1 | ABBVIE INC. | $5,785.50 | 12/04/2025 | Non-covered Recipient Entity ARANO PLLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202528156 |
| Principal investigator 1 | ABBVIE INC. | $5,689.20 | 12/04/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202528170 |
| Principal investigator 1 | Incyte Corporation | $1,436.10 | 12/04/2025 | Non-covered Recipient Entity ILLINOIS DERMATOLOGY INSTITUTE THE CHICAGO LOOP | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240538980 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 12/01/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240525619 |
| Principal investigator 1 | Incyte Corporation | $1,211.40 | 11/25/2025 | Non-covered Recipient Entity ILLINOIS DERMATOLOGY INSTITUTE THE CHICAGO LOOP | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240538975 |
| Principal investigator 1 | ABBVIE INC. | $4,630.80 | 11/04/2025 | Non-covered Recipient Entity ARANO PLLC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202520629 |
| Principal investigator 1 | ABBVIE INC. | $5,760.00 | 11/04/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202520631 |
| Principal investigator 1 | Incyte Corporation | $1,211.40 | 10/29/2025 | Non-covered Recipient Entity ILLINOIS DERMATOLOGY INSTITUTE THE CHICAGO LOOP | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240538970 |
| Principal investigator 1 | ABBVIE INC. | $3,985.00 | 10/09/2025 | Non-covered Recipient Entity DENOVA RESEARCH | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202515551 |
| Principal investigator 1 | ABBVIE INC. | $6,888.60 | 10/09/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202515553 |
| Principal investigator 1 | ABBVIE INC. | $5,038.80 | 10/09/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202515555 |
| Principal investigator 1 | ABBVIE INC. | $12,600.00 | 10/09/2025 | Non-covered Recipient Entity ARANO PLLC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202515557 |
| Principal investigator 1 | Incyte Corporation | $6,000.00 | 10/09/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240525610 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 10/09/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240525614 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $38,269.13 | 10/08/2025 | Non-covered Recipient Entity ILLINOIS DERMATOLOGY INSTITUTE, LLC | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S | No dispute reported | 06/30/2026 | 1190308022 |
| Principal investigator 1 | Incyte Corporation | $1,650.60 | 09/23/2025 | Non-covered Recipient Entity ILLINOIS DERMATOLOGY INSTITUTE THE CHICAGO LOOP | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240538960 |
| Principal investigator 1 | ABBVIE INC. | $310.17 | 09/22/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202511718 |
| Principal investigator 1 | Incyte Corporation | $4,854.60 | 09/12/2025 | Non-covered Recipient Entity ILLINOIS DERMATOLOGY INSTITUTE THE CHICAGO LOOP | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240538963 |
| Principal investigator 1 | ABBVIE INC. | $900.00 | 09/11/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202510600 |
| Principal investigator 1 | ABBVIE INC. | $494.00 | 09/04/2025 | Non-covered Recipient Entity DENOVA RESEARCH | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202508496 |
| Principal investigator 1 | Incyte Corporation | $2,278.80 | 09/04/2025 | Non-covered Recipient Entity ILLINOIS DERMATOLOGY INSTITUTE THE CHICAGO LOOP | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240538966 |
| Principal investigator 1 | ABBVIE INC. | $8,958.60 | 09/03/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202507165 |
| Principal investigator 1 | ABBVIE INC. | $8,431.20 | 09/03/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202507167 |
| Principal investigator 1 | Incyte Corporation | $1,718.10 | 08/26/2025 | Non-covered Recipient Entity ILLINOIS DERMATOLOGY INSTITUTE THE CHICAGO LOOP | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240538956 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,240.50 | 08/25/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175337555 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,000.00 | 08/18/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175337578 |
| Principal investigator 1 | ABBVIE INC. | $2,293.60 | 08/06/2025 | Non-covered Recipient Entity DENOVA RESEARCH | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202502362 |
| Principal investigator 1 | ABBVIE INC. | $14,467.20 | 08/05/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202501176 |
| Principal investigator 1 | ABBVIE INC. | $7,337.40 | 08/05/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202501224 |
| Principal investigator 1 | Eli Lilly and Company | $5,940.79 | 07/17/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) | No dispute reported | 06/30/2026 | 1187881692 |
| Principal investigator 1 | Eli Lilly and Company | $4,500.00 | 07/15/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) | No dispute reported | 06/30/2026 | 1187881342 |
| Principal investigator 1 | ABBVIE INC. | $6,754.80 | 07/02/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202494025 |
| Principal investigator 1 | ABBVIE INC. | $6,817.80 | 07/02/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202496683 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,000.00 | 06/30/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175337571 |
| Principal investigator 1 | ABBVIE INC. | $8,346.00 | 06/03/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202488309 |
| Principal investigator 1 | ABBVIE INC. | $1,086.60 | 06/03/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202488311 |
| Principal investigator 1 | Eli Lilly and Company | $64,967.65 | 06/03/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS | No dispute reported | 06/30/2026 | 1187882468 |
| Principal investigator 1 | ABBVIE INC. | $1,993.60 | 05/07/2025 | Non-covered Recipient Entity DENOVA RESEARCH | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202483931 |
| Principal investigator 1 | ABBVIE INC. | $15,487.20 | 05/07/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202483933 |
| Principal investigator 1 | ABBVIE INC. | $14,436.00 | 05/06/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202482175 |
| Principal investigator 1 | Eli Lilly and Company | $4,938.08 | 04/23/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS | No dispute reported | 06/30/2026 | 1187879727 |
| Principal investigator 1 | ABBVIE INC. | $9,490.80 | 04/03/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202472066 |
| Principal investigator 1 | ABBVIE INC. | $13,959.60 | 04/03/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202472082 |
| Principal investigator 1 | ABBVIE INC. | $2,990.00 | 04/03/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202472775 |
| Principal investigator 1 | ABBVIE INC. | $5,084.40 | 03/07/2025 | Non-covered Recipient Entity DENOVA RESEARCH | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202459845 |
| Principal investigator 1 | ABBVIE INC. | $7,990.80 | 03/07/2025 | Non-covered Recipient Entity DENOVA RESEARCH | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202459850 |
| Principal investigator 1 | Eli Lilly and Company | $67,200.00 | 02/18/2025 | Non-covered Recipient Entity DENOVA RESEARCH | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187878721 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,233.00 | 02/10/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175337562 |
| Principal investigator 1 | ABBVIE INC. | $13,125.60 | 02/06/2025 | Non-covered Recipient Entity DENOVA RESEARCH | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202447062 |
| Principal investigator 1 | ABBVIE INC. | $12,936.60 | 02/06/2025 | Non-covered Recipient Entity DENOVA RESEARCH | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202447066 |
| Principal investigator 1 | ABBVIE INC. | $2,274.40 | 02/06/2025 | Non-covered Recipient Entity DENOVA RESEARCH | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202447070 |
| Principal investigator 1 | Amgen Inc. | $42,285.14 | 01/27/2025 | Non-covered Recipient Entity DENOVA RESEARCH | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246640685 |
| Principal investigator 1 | Eli Lilly and Company | $3,192.57 | 01/27/2025 | Non-covered Recipient Entity DENOVA RESEARCH | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187878187 |